{"id":573243,"date":"2025-12-03T00:00:00","date_gmt":"2025-12-03T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2025-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2025\/"},"modified":"2026-03-31T10:24:07","modified_gmt":"2026-03-31T10:24:07","slug":"dlsfcg0001-2025-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2025","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0001-2025-biopharma-alzheimers-disease-disease-landscape-and-forecast-g7-2025\/","title":{"rendered":"Alzheimer&#8217;s Disease | Disease Landscape and Forecast | G7 | 2025"},"content":{"rendered":"<p>Eisai \/ Biogen\u2019s lecanemab (Leqembi) and Eli Lilly\u2019s Kisunla (donanemab) have launched for the treatment of early Alzheimer\u2019s disease (AD) in the United States and Japan and, after early headwinds, are nearing market in Europe. Early uptake of the anti-A\u03b2 MAbs has been slow, but market-building efforts to drive awareness and streamline diagnosis are ongoing. New formulations (e.g., subcutaneous lecanemab) and potentially disruptive DMTs (e.g., Roche\u2019s trontinemab, Eli Lilly\u2019s remternetug, Novo Nordisk\u2019s semaglutide) are advancing in the pipeline. Lundbeck \/ Otsuka\u2019s brexpiprazole (Rexulti) is FDA-approved to treat agitation in AD, and other novel therapies, including Axsome\u2019s dextromethorphan-bupropion (Auvelity) and Karuna\u2019s xanomeline-trospium (Cobenfy), are progressing through late-phase development to treat the neuropsychiatric symptoms of AD. The launch of these potential blockbusters could meaningfully alter this market\u2019s dynamics, driven by unmet clinical need, market demand, and brand-level pricing.<\/p>\n<ul>\n<li>How will competition between current and emerging anti-A\u03b2 MAbs evolve through 2034?<\/li>\n<li>How do KOLs perceive recently approved and emerging neuropsychiatric therapies for AD? What are the key opportunities for differentiation in this area?<\/li>\n<li>What are the key drivers of and constraints on the AD market, and how might they change over the forecast period?<\/li>\n<li>What impact could the launch of an oral DMT have on the market?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul>\n<li>Optimize your long-term disease and development strategy.<\/li>\n<\/ul>\n<ul>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<\/ul>\n<ul>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<\/ul>\n<ul>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-573243","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573243\/revisions"}],"predecessor-version":[{"id":575270,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/573243\/revisions\/575270"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=573243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}